Treace Medical Concepts Inc TMCI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TMCI is a good fit for your portfolio.
News
-
Treace to Present at Bank of America Health Care Conference
-
Treace Announces First Annual National Bunion Day
-
Treace to Report First Quarter 2024 Financial Results
-
Treace Celebrates 100,000 Lapiplasty® 3D Bunion Correction® Patient Milestone
-
Treace Medical Concepts Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Guidance
-
Treace to Report Fourth Quarter and Full-Year 2023 Financial Results
-
Treace Announces Interim 3-Year ALIGN3D™ Clinical Study Data at the 2024 ACFAS Scientific Conference Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure
-
Treace to Highlight Latest Product Innovations and ALIGN3D™ Study Outcomes at the 2024 ACFAS Annual Scientific Conference
Trading Information
- Previous Close Price
- $10.97
- Day Range
- $10.77–11.21
- 52-Week Range
- $5.27–27.70
- Bid/Ask
- $6.00 / $14.30
- Market Cap
- $687.49 Mil
- Volume/Avg
- 270,025 / 406,452
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.57
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Growth
- Total Number of Employees
- 227
- Website
- https://www.treace.com
Comparables
Valuation
|
Metric
|
TMCI
|
SIBN
|
FNA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.91 | 3.68 | 4.50 |
Price/Sales | 3.57 | 4.23 | 3.66 |
Price/Cash Flow | — | — | — |
Price/Earnings
TMCI
SIBN
FNA
Financial Strength
|
Metric
|
TMCI
|
SIBN
|
FNA
|
|---|---|---|---|
Quick Ratio | 3.58 | 8.01 | 2.22 |
Current Ratio | 4.40 | 9.01 | 4.21 |
Interest Coverage | −9.89 | −13.52 | −8.22 |
Quick Ratio
TMCI
SIBN
FNA
Profitability
|
Metric
|
TMCI
|
SIBN
|
FNA
|
|---|---|---|---|
Return on Assets (Normalized) | −21.53% | −8.97% | −11.27% |
Return on Equity (Normalized) | −38.46% | −12.61% | −18.48% |
Return on Invested Capital (Normalized) | −25.74% | −11.78% | −12.43% |
Return on Assets
TMCI
SIBN
FNA
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Qhzkkmss | Jhcqxlf | $185.8 Bil | |
SYK
| Stryker Corp | Lklwfffj | Mbjct | $124.7 Bil | |
MDT
| Medtronic PLC | Kllrdlqpb | Mgbqntj | $105.2 Bil | |
BSX
| Boston Scientific Corp | Qrrjkzswb | Crvxjl | $99.0 Bil | |
EW
| Edwards Lifesciences Corp | Rccsjcgjqx | Mlqfyz | $52.3 Bil | |
DXCM
| DexCom Inc | Mmqqdntdg | Vry | $52.1 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Cmdrznhvd | Plby | $24.8 Bil | |
ALGN
| Align Technology Inc | Fmqnqgr | Ncvmgpv | $22.6 Bil | |
PHG
| Koninklijke Philips NV ADR | Xhvdwlmx | Ftqbd | $18.5 Bil | |
PODD
| Insulet Corp | Hrkrvztwxp | Bmbfl | $11.5 Bil |